Giant Biogene Reports Stable Capital Structure for May 2026; 0.67 Million Share Options Lapse

Bulletin Express06-04

Giant Biogene Holding Co., Ltd. filed its Monthly Return for the period ended 31 May 2026 on 4 June 2026. Key data from the submission to the Hong Kong Stock Exchange are as follows:

• Authorised share capital remained unchanged at 5.00 billion ordinary shares with a par value of USD 0.00001, equivalent to USD 50,000.

• Issued share capital was steady at 1.06 billion shares; no treasury shares were held or cancelled during the month.

• The company confirmed compliance with the Main Board’s minimum public-float requirement of 25 percent.

• Under the 2023 Share Option Scheme, 0.67 million options lapsed in May, reducing outstanding options to 10.93 million. No options were exercised, no new shares were issued, and no funds were raised. The scheme still permits the future issuance of up to 80.89 million shares.

The absence of share issuances, repurchases, or new treasury shares indicates a stable equity structure for Giant Biogene over the reporting month.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment